New research reveals that people who stop using new weight-loss injections like semaglutide or tirzepatide can put back on lost weight much more quickly than those who end traditional diet and exercise plans.
Research printed in a leading medical journal shows that while obese individuals frequently drop a large proportion of their body weight while on the medication, the mass is regained at an average rate of 0.8 kg per month after stopping.
"Individuals using such treatments need to be informed of the potential of quick weight regain when the medication ends," warns lead investigator Dr. Susan Jebb.
That rate of regain implies a return to original mass within about one and a half years.
Analyzing Therapies
The research, which examined 37 of trials involving over 9,000 of participants, compared the outcomes of the injectable medications with other pills.
Scientists note that people who lose weight through diet and exercise typically see a less rapid weight regain—perhaps 0.1 kg a month—after stopping.
Explaining the Quick Rebound
Doctors suggest the way of the drugs accounts for the amplified rebound.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production could lead to the system to produce less of its endogenous GLP-1, and may also lessen sensitivity to its effects," said Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this hormone supplement results in appetite is uncontrolled, making binge eating much more probable."
A Chronic Condition?
The NHS suggest the injections for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications.
A number of clinicians argue that, due to the high risk of relapse, the treatment is often long-term.
This view is supported by drug manufacturers, who note that the findings "underscore the persistent nature of obesity," similar to managing diseases like diabetes.
User Accounts
Users who have discontinued the jabs describe a intense return of hunger.
"It was like a trigger flipping and I was suddenly extremely hungry," recalled one woman.
The struggle is compounded if patients have not adopted sustainable dietary or behavioural changes during treatment.
Widespread Use
Recent estimates show that millions of adults in the UK have tried these injections in the last 12 months, with desire remaining high.
- Adoption is greater among females than males.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
Ultimately, clinicians emphasize that while these medications are powerful tools for weight loss, they are not a magic solution and long-term success hinges on integrated lifestyle management.
